Page results
-
This page aims to help you decide if a post-dates induction of labour is the right decision for you and your baby.
-
This page has been written for patients at Eastman Dental Hospital who are undergoing intravenous sedation.
-
A team of clinician scientists at UCLH have identified the factors which predict full hearing recovery, with the strongest predictor being treatment with steroids within seven days of a sudden drop in hearing.
-
The UCLH children’s FGC/M clinic provides specialist care for children and adolescents who have undergone or are at risk of FGC/M.
-
This step-by-step guide explains how you can give yourself an injection of bortezomib at home.
-
Patient Partners are patients, carers, families and people with lived experience of a specific issue or service. UCLH is committed to involving patients, carers, and members of the public in planning, developing, delivering, and monitoring the services we provide. Involving patients and the public in decision-making is crucial to ensuring that those services are what patients want and need.
-
This page explains the use of botulinum toxin in the management of facial weakness and synkinesis as part of treatment process in the complex facial clinic.
-
To mark International Brain Tumour Awareness Week, UCLH and The National Brain Appeal are announcing a new clinical trial for patients with recurrent glioblastoma brain cancer.
-
This page explains what FACETS is and how it can help you.
-
Three patients in the UK have received an innovative treatment for the most serious form of lupus – an autoimmune condition which can cause damage to the heart, lungs, joints, brain or kidneys.
File results
-
FOI/2022/206 - Rates for Bonham Carter House 52-54 Gower Street
-
FOI/2022/0207 - Patient treatment with Nivolumab
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services